Maryland earmarks another $500M for biotech

Maryland is upping its ante in an ambitious bid to attract biotech companies to the state. Just days after the state took the spotlight at BIO with an announced plan to provide $1.1 billion of incentives for the industry, state officials now say they will invest up to $500 million of state pension money in the field--with Maryland-based biotechs getting the lion's share of the money.

"We're serious in Maryland about growing and supporting the industry," said Comptroller Peter Franchot.

California went a long way to setting the pace for state biotech initiatives with its $3 billion stem cell plan. And Massachusetts has gained considerable attention with its new $1 billion program. It seems like it takes at least 10 figures to grab headlines in the economic development field these days.

- read the article in the Baltimore Sun

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.